Novel Therapeutic Approaches
Current therapies for chronic hepatitis B can suppress HBV replication, but long-term therapy is required in most patients. It is therefore imperative that we continue the search for alternative methods of viral eradication.
HBV core (capsid) protein plays a role in HBV persistence. NVR 3-778 is an HBV core inhibitor that can potentially inhibit viral assembly, HBV genome replication, cccDNA replenishment, and hepatic reinfection cycles.
Yuen and colleagues reported clinical proof-of-concept data from a multicenter phase 1b trial in HBeAg-positive patients randomly assigned to receive NVR 3-778 capsules for 28 days in various doses (100, 200, or 400 mg once daily or 600 mg twice daily). The safety and tolerability of NVR 3-778 were satisfactory for all cohorts, with no treatment-related discontinuations or serious adverse events. Small HBV DNA reductions were apparent following the 200-mg and 400-mg once-daily dose. Of note, tripling of the daily dose to 1200 mg (600 mg twice daily) increased the mean 28-day reduction in serum HBV DNA levels. Pharmacokinetic data indicated multimicromolar concentrations of NVR 3-778 that supported once-daily or twice-daily dosing, with dose-related increases in drug levels.
When used alone or in combination with current HBV antivirals, NVR 3-778 may offer an additive antiviral effect via unique core-related mechanisms and advance clinical care closer to the desired goal of increased durable response rates in patients with chronic hepatitis B.
Medscape Gastroenterology © 2016 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Hepatitis B Takes Center Stage - Medscape - Mar 30, 2016.